$ACB

Cannabis Stock Gainers And Losers From April 11, 2025 - Aurora Cannabis (NASDAQ:ACB), Aleafia Health (OTC:ALEAF)

Aleafia Health ALEAF shares closed up 900.00% at $1e-05 CordovaCann LVRLF shares closed up 31.84% at $0.10 iAnthus Capital Hldgs ITHUF shares closed up 21.33% at $0.01 Urban-gro UGRO shares closed up 15.18% at $0.57 SOL Glb Inv SOLCF shares closed up 14.62% at $0.06

Original reporting
Benzinga · Benzinga Insights
Published Apr 11, 2025, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 11, 2025, 9:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cannabis Stock Gainers And Losers From April 11, 2025 - Aurora Cannabis (NASDAQ:ACB), Aleafia Health (OTC:ALEAF) — source image
Decision brief

The 30-second read

$ACBBullishMed
01

Why it matters

The notable price increases suggest heightened trading activity and investor interest, but also increased risk of sharp corrections.

02

Market read

The recent positive developments and stock surges highlight increased investor interest and potential sector growth, but caution is advised due to volatility.

03

What to watch

Sector-wide regulatory changes, macroeconomic factors, or profit-taking could reverse the bullish trend and lead to increased volatility.

Timing: Immediate to short-term (next 1-2 weeks)

Background

The cannabis sector has experienced significant volatility, with recent surges driven by positive news, sector optimism, and investor speculation.

Company-level read

Ticker impact

$ACBBullishMedium confidence
Context

Moderate relevance; sentiment is bullish but with less dramatic price change.

Expected impact

Likely to see continued upward movement in the short term, barring negative news.

Evidence & confidence

Market sentiment is favorable, but trading volume and liquidity should be monitored for confirmation.

$ITHUFBullishMedium confidence
Context

High relevance; notable price increase and bullish sentiment.

Expected impact

Likely continuation of upward momentum in the near term.

Evidence & confidence

Market sentiment supports further gains, but external factors could influence volatility.

$UGROBullishMedium confidence
Context

High relevance; strong bullish sentiment and notable price increase.

Expected impact

Possible continuation of upward trend, with caution for profit-taking.

Evidence & confidence

Market momentum suggests further gains, but technical levels should be analyzed.

Market effects

The positive sentiment and price surges in cannabis stocks indicate a bullish phase in the life sciences and retail sectors related to cannabis.

Potentially favorable impact on North American cannabis markets, with increased investor interest.

Limited; primarily regional effects, but could influence global cannabis industry sentiment.

Counterpoint

The recent surge in certain cannabis stocks may be driven by speculative trading rather than fundamental improvements, risking a sharp correction.

Key entities

  • Aleafia Health

    A Canadian-based medical and recreational cannabis company.

  • Aurora Cannabis

    A major Canadian cannabis producer.

  • Urban-gro

    A provider of controlled environment agriculture technology.

  • 22nd Century Group

    A biotech company focused on plant biotechnology and tobacco harm reduction.

  • Cura Cannabis

    A Canadian cannabis producer.

Related articles

$ACBMedAI 8/10

Aurora Cannabis Announces Fiscal 2027 First Quarter Results

Aurora Cannabis (NASDAQ: ACB, TSX: ACB) reported fiscal 2027 Q1 results for the quarter ended June 30, 2026. Net revenue was $67.6 million, down from $74.1 million. International medical cannabis net revenue rose 17% to $43.3 million, while Canadian medical cannabis fell 25% to $20.7 million. The company had $149.1 million cash and no debt, and posted a $4.0 million net loss from continuing operations.

$ACBMed

Aurora Cannabis Q1 Earnings Call Highlights

Aurora Cannabis (ACB) reported Q1 adjusted SG&A of C$35.1M, down from C$36.1M a year earlier. Free cash flow was a C$5.8M outflow versus a C$6.8M inflow prior year, tied to lower gross profit before fair-value adjustments. Aurora ended with nearly C$150M cash and no debt, acquired Safari Flower, and reaffirmed its fiscal 2027 outlook.

$ACBMed

Aurora Cannabis Swings To Negative Cash Flow In Q1 2027

Aurora Cannabis (ACB) reported Q1 fiscal 2027 net revenue of $67.6M, down 9% YoY and 20% QoQ. Medical revenue was $64.0M, with Canadian medical down 25% YoY to $20.7M after a federal reimbursement change. Loss from continuing ops was $4.0M and free cash flow was -$5.8M. Cash fell to $149.1M.

$ACBMedAI 8/10

Aurora Cannabis Announces Fiscal 2027 First Quarter Results

Aurora Cannabis (NASDAQ: ACB, TSX: ACB) reported fiscal 2027 Q1 results for the quarter ended June 30, 2026. Net revenue fell to $67.6M from $74.1M, while international medical cannabis net revenue rose 17% to $43.3M. Net loss from continuing operations was $4.0M. The company said it has $149.1M cash and no debt and that Safari Flower received EU-GMP certification.